Q2 EARNINGS: Alere plans restructure after weak quarter
This article was originally published in Clinica
Alere’s stock fell 13% to close at $34.75 on 4 August after it reported another disappointing quarter. Q2 sales were down 3% year-on-year at $737.9m, missing analyst consensus expectations of $748m. Its health information solutions segment did particularly badly: revenues in the unit dipped 7% to $125.8m. Meanwhile, its professional diagnostics franchise was down 3% at $583.4m.